LLY is trading at 3.01% down now at $1,071.06 following a $178.42 million share sale by Lilly Endowment Inc on November 25, which reduced the endowment's holdings to 92.196 million shares. The transaction triggered short-term market volatility and investor concern about portfolio rebalancing, coinciding with broader biotech/pharma sector weakness. While the sale doesn't impact operational performance, it signaled a strategic shift in the major shareholder's investment approach.